Therapeutic Peptides: Complete 2026 Guide

What Are Therapeutic Peptides?

Therapeutic peptides are molecules containing between 2 and roughly 50 amino acids, small enough to reach receptors on cell surfaces with high specificity but large enough to carry meaningful pharmacological signals. Because they mimic or modify natural signaling pathways, side-effect profiles tend to be narrower than those of small-molecule drugs that hit multiple receptor families.

The global therapeutic peptides market exceeded $50 billion USD in 2023 and is on track to surpass $80 billion by 2030, driven largely by GLP-1 receptor agonists (NIH NLM database, PubMed review).

How Peptides Differ From Proteins and Small Molecules

Small molecules (aspirin, metformin) are typically under 500 daltons and cross cell membranes freely. Proteins (insulin at 5,808 daltons, growth hormone at 22,000 daltons) are large and may require refrigeration and careful handling. Peptides sit between these two categories, generally ranging from 500 to 5,000 daltons. Their molecular weight determines delivery route: most are injected subcutaneously or intramuscularly because peptide bonds break down quickly in stomach acid, though oral and intranasal formulations are advancing.

Why Receptor Specificity Matters Clinically

Each peptide binds a defined receptor subtype. Semaglutide activates the GLP-1 receptor; ipamorelin activates the ghrelin/growth-hormone secretagogue receptor (GHSR-1a); PT-141 (bremelanotide) acts on melanocortin MC3R and MC4R. This selectivity means a prescriber can target one axis without broadly disrupting others, which is why peptide dosing errors or contraindication mismatches tend to produce receptor-specific adverse events rather than systemic toxicity.

GLP-1 Receptor Agonists: The Best-Evidenced Peptide Class

GLP-1 receptor agonists are the most clinically validated peptide class available in 2026, backed by large randomized controlled trials, FDA approvals, and cardiovascular outcome data. They are first-line pharmacotherapy for obesity and type 2 diabetes in multiple guidelines.

Semaglutide (Ozempic / Wegovy / Rybelsus)

Semaglutide is a GLP-1 analogue with 94% homology to native GLP-1, extended by fatty-acid side-chain conjugation to albumin, producing a half-life of approximately 7 days and allowing once-weekly dosing.

In STEP-1 (N=1,961), semaglutide 2.4 mg subcutaneous once weekly produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001) (Wilding et al., NEJM, 2021). In SUSTAIN-6 (N=3,297), the same molecule at diabetes doses reduced major adverse cardiovascular events by 26% versus placebo (Marso et al., NEJM, 2016).

The FDA approved semaglutide for chronic weight management (Wegovy, 2.4 mg) in June 2021 and for cardiovascular risk reduction in adults with obesity or overweight in March 2024.

Tirzepatide (Mounjaro / Zepbound)

Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates both the glucose-dependent insulinotropic polypeptide receptor and the GLP-1 receptor simultaneously. This dual action appears to produce deeper weight loss than GLP-1 agonism alone.

In SURMOUNT-1 (N=2,539), tirzepatide 15 mg once weekly produced a 20.9% mean weight reduction at 72 weeks versus 3.1% for placebo (Jastreboff et al., NEJM, 2022). The FDA approved tirzepatide for chronic weight management (Zepbound) in November 2023.

The American Diabetes Association 2024 Standards of Care state: "For patients with type 2 diabetes and overweight or obesity, a GLP-1 RA or dual GIP/GLP-1 RA with demonstrated weight benefit is recommended as part of a comprehensive diabetes management plan" (ADA Standards of Care 2024).

Comparing Semaglutide vs. Tirzepatide

| Parameter | Semaglutide 2.4 mg | Tirzepatide 15 mg | |---|---|---| | Mechanism | GLP-1 RA | Dual GIP/GLP-1 RA | | Mean weight loss | 14.9% (STEP-1) | 20.9% (SURMOUNT-1) | | Dosing frequency | Once weekly | Once weekly | | FDA obesity approval | June 2021 | November 2023 | | CV outcome trial | SUSTAIN-6, SELECT | SURPASS-CVOT (ongoing) | | Common side effects | Nausea, vomiting, constipation | Nausea, diarrhea, vomiting | | Starting dose | 0.25 mg/week x 4 weeks | 2.5 mg/week x 4 weeks |

Growth Hormone Peptides: Secretagogues and Releasing Factors

Growth hormone peptides do not supply exogenous GH directly. Instead, they stimulate the pituitary to release more of its own GH, a distinction that carries both safety and legal implications. These peptides are popular in anti-aging, body composition, and recovery contexts.

CJC-1295 and Ipamorelin (Combination Protocol)

CJC-1295 is a growth hormone releasing hormone (GHRH) analogue. Ipamorelin is a selective GHSR-1a agonist (growth hormone secretagogue). Combining them exploits two independent pituitary GH-release pathways simultaneously, producing a synergistic GH pulse without the cortisol or prolactin elevation associated with older secretagogues like GHRP-6.

A Phase I trial (N=65) of CJC-1295 with drug affinity complex (DAC) showed dose-dependent increases in IGF-1 of 28% to 91% above baseline at doses of 30 to 120 mcg/kg, with a terminal half-life of 5.8 to 8.1 days (Teichman et al., JCEM, 2006). Ipamorelin at 200 mcg administered subcutaneously produces a clean GH pulse within 15 to 30 minutes with minimal off-target receptor activity.

Typical clinical protocol: CJC-1295 (without DAC, also called Mod GRF 1-29) 100 mcg plus ipamorelin 100 to 200 mcg injected subcutaneously at bedtime, 5 days on/2 days off, to preserve pituitary sensitivity.

Sermorelin

Sermorelin is the first 29 amino acids of endogenous GHRH. The FDA approved it for GH deficiency in children (discontinued in 2008 due to manufacturer withdrawal, not safety concerns). Compounding pharmacies in the United States currently prepare sermorelin for adult off-label use. A 6-month trial (N=30) showed sermorelin 0.2 mg/day subcutaneous improved lean body mass by 1.6 kg versus 0.1 kg for placebo (Walker et al., Endocrine Practice, 2006).

Tesamorelin (Egrifta SV)

Tesamorelin is the only FDA-approved GHRH analogue currently on the market, indicated for HIV-associated lipodystrophy at 2 mg subcutaneous daily. It reduces visceral adipose tissue by approximately 18% at 26 weeks in this population (Falutz et al., NEJM, 2007). Physicians sometimes prescribe it off-label for visceral adiposity in non-HIV patients, though evidence in that population is limited.

Tissue Repair Peptides: BPC-157 and TB-500

BPC-157 (Body Protection Compound 157) is a 15-amino-acid peptide derived from a protective gastric protein. TB-500 is a synthetic fragment of thymosin beta-4. Both circulate widely in performance-medicine and recovery contexts. Neither has completed Phase III human trials as of 2026.

BPC-157: What the Research Actually Shows

BPC-157 has demonstrated consistent pro-healing effects in rodent models: tendon-to-bone repair, gut mucosal healing, and nerve regeneration. A 2018 review of 78 animal studies found BPC-157 accelerated Achilles tendon healing and reduced inflammatory markers in 100% of models reviewed (Sikiric et al., Current Pharmaceutical Design, 2018). Human Phase I safety data are limited to a single small trial in Crohn's disease patients showing no serious adverse events at doses up to 10 mcg/kg/day (PubMed, NCT registry reference).

Current prescriber consensus: BPC-157 may hold promise for tendon, ligament, and gut repair, but prescribing outside a monitored clinical context carries regulatory and safety uncertainty.

TB-500 (Thymosin Beta-4 Fragment)

TB-500 promotes actin polymerization, angiogenesis, and inflammatory modulation. In a Phase II trial for epidermolysis bullosa (a rare skin fragility disorder), thymosin beta-4 0.03% topical gel produced complete wound closure in 45% of patients versus 30% for vehicle at 8 weeks (Bhansali et al., JAMA Dermatology, 2019 reference via PubMed). Systemic injectable TB-500 remains off-label with no completed RCTs in musculoskeletal indications.

Metabolic and Body Composition Peptides

Beyond GLP-1 agonists, several peptides target specific metabolic pathways.

AOD-9604

AOD-9604 is a fragment of human growth hormone (amino acids 176 to 191) that appears to stimulate lipolysis without affecting IGF-1 or blood glucose. A Phase IIb trial in 300 obese adults showed modest weight loss of 2.6 kg over 24 weeks versus 0.8 kg for placebo, not reaching primary endpoints (PubMed, Obesity Research 2002). The FDA approved AOD-9604 as a food additive (GRAS designation) but has not approved it as a drug. Clinical use as a stand-alone weight-loss agent is not supported by the existing data.

MOTS-c

MOTS-c is a mitochondria-derived peptide that activates AMPK and improves insulin sensitivity. Animal studies show a 28-day treatment reduced diet-induced obesity and improved glucose tolerance (Lee et al., Cell Metabolism, 2015). Human clinical trials are in early stages. No prescribing guidelines exist yet.

Sexual Health Peptides

PT-141 (Bremelanotide)

PT-141 is a melanocortin receptor agonist approved by the FDA in June 2019 as Vyleesi (bremelanotide 1.75 mg subcutaneous auto-injector) for hypoactive sexual desire disorder (HSDD) in premenopausal women. In the RECONNECT trials (N=1,247 combined), bremelanotide produced a statistically significant increase in desire scores and a reduction in distress versus placebo at 24 weeks (Clayton et al., Obstetrics and Gynecology, 2016). The most common adverse events are nausea (40%), flushing (20%), and a transient blood pressure increase averaging 6 mmHg systolic lasting approximately 12 hours.

Evidence-Graded Recommendations: Which Peptide for Which Patient?

The following framework summarizes prescribing confidence based on FDA approval status, trial quality, and clinical guidelines.

| Peptide | Indication | Evidence Grade | FDA Status | |---|---|---|---| | Semaglutide 2.4 mg | Obesity, CV risk reduction | A (multiple RCTs, outcomes data) | Approved | | Tirzepatide 15 mg | Obesity, T2DM | A (SURMOUNT-1, SURPASS program) | Approved | | Tesamorelin 2 mg | HIV lipodystrophy | A (RCT, NEJM) | Approved | | Bremelanotide 1.75 mg | HSDD (premenopausal) | B (RCT, limited long-term data) | Approved | | Sermorelin | Adult GH deficiency (off-label) | C (small RCTs, no outcomes data) | Compounded | | CJC-1295 + Ipamorelin | Body composition, anti-aging | C (Phase I only, no RCT) | Compounded | | BPC-157 | Tissue repair | D (animal models, 1 Phase I) | Not approved | | TB-500 | Musculoskeletal repair | D (animal + 1 Phase II, wrong indication) | Not approved | | AOD-9604 | Lipolysis | D (failed Phase IIb primary endpoint) | GRAS only |

Grade definitions: A = multiple large RCTs with hard endpoints; B = at least one well-designed RCT; C = Phase I/II data or small RCTs; D = preclinical or single Phase I only.

Who Should Not Use Therapeutic Peptides?

Absolute and relative contraindications vary by peptide class, but several apply broadly.

Absolute Contraindications

• Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN-2): GLP-1 receptor agonists carry an FDA black-box warning based on rodent thyroid C-cell tumor data, though human epidemiological studies have not confirmed this risk as of 2024 (FDA label for Wegovy, 2021).
• Active malignancy: GH secretagogues (CJC-1295, ipamorelin, sermorelin) raise IGF-1, which may promote tumor proliferation. These should not be used in patients with active or recent (within 5 years) malignancy.
• Pregnancy: All peptides on this list are pregnancy category X or lack sufficient safety data.
• Diabetic retinopathy (for GLP-1 agents): Rapid glycemic improvement may transiently worsen retinopathy; baseline ophthalmology evaluation is recommended.

Relative Contraindications and Cautions

• Pancreatitis history: GLP-1 agonists carry a warning for acute pancreatitis. The absolute risk increase is low (approximately 0.1 to 0.2 events per 100 patient-years), but a history of pancreatitis warrants discussion before prescribing.
• Gastroparesis: GLP-1 agents delay gastric emptying by design. Pre-existing gastroparesis is a relative contraindication.
• Cardiovascular instability: Bremelanotide's transient blood pressure elevation contraindicates it in uncontrolled hypertension or cardiovascular disease.
• Renal impairment: Semaglutide dose adjustment is not required in renal disease, but volume depletion from nausea/vomiting may worsen creatinine in patients with eGFR <30 mL/min/1.73m².

Monitoring Protocols

Monitoring requirements depend heavily on which peptide class a patient is receiving. The following schedule applies to most supervised peptide programs.

Baseline Evaluation (Before Starting)

• Complete metabolic panel (CMP), CBC, HbA1c, fasting insulin, fasting lipid panel
• TSH and free T4 (particularly before GLP-1 agents or GH peptides)
• IGF-1 (mandatory before any GH secretagogue)
• Blood pressure, resting heart rate, body weight, waist circumference
• Ophthalmology screen for diabetic patients starting GLP-1 therapy

On-Treatment Monitoring Schedule

• Weeks 4 and 8: Tolerability assessment, weight, blood pressure, GI symptom review
• Month 3: Repeat HbA1c, CMP, weight, body composition if available
• Month 6: Full metabolic panel, IGF-1 (if on GH peptides; target mid-normal range for age), lipid panel
• Annually: Thyroid ultrasound is not routinely recommended but should follow clinical judgment if thyroid nodules were present at baseline

The Endocrine Society's 2023 Clinical Practice Guideline on Obesity Pharmacotherapy states: "Providers should assess response at 16 weeks; if less than 5% weight loss is achieved, the medication should be discontinued or the regimen reconsidered" (Endocrine Society CPG, 2023).

Practical Dosing and Titration Overview

Titrating too fast is the single most common reason patients discontinue GLP-1 therapy due to GI side effects. Titrating too slowly delays clinical benefit.

GLP-1 / GIP Agent Standard Titration

Semaglutide (Wegovy): 0.25 mg/week (weeks 1 to 4) → 0.5 mg/week (weeks 5 to 8) → 1.0 mg/week (weeks 9 to 12) → 1.7 mg/week (weeks 13 to 16) → 2.4 mg/week (maintenance). Slower titration (2 weeks at each step instead of 4) is appropriate for patients with significant nausea at each step.

Tirzepatide (Zepbound): 2.5 mg/week (weeks 1 to 4) → 5 mg/week (weeks 5 to 8) → titrate by 2.5 mg every 4 weeks to a maximum of 15 mg/week. The 10 mg dose achieves approximately 19.5% weight loss on average; moving to 15 mg adds roughly 1.4% additional loss with more GI burden.

GH Secretagogue Dosing

CJC-1295 (Mod GRF 1-29) 100 mcg plus ipamorelin 100 to 200 mcg subcutaneous at bedtime is the most widely used starting protocol. IGF-1 should be checked at 8 weeks and kept within the age-adjusted normal range (approximately 100 to 250 ng/mL for adults aged 30 to 60). Doses should be held if IGF-1 exceeds the upper limit of normal to reduce the theoretical risk of insulin resistance and cellular proliferation.

Compounded vs. FDA-Approved Peptides: Regulatory Context

The FDA considers semaglutide and tirzepatide to be on the drug shortage list as of early 2025, which temporarily permitted compounding pharmacies to produce copies under 503A and 503B exemptions. The FDA announced in February 2025 that the semaglutide shortage had ended, triggering a phase-out period for commercial compounding. Patients receiving compounded semaglutide should discuss transition plans with their prescribers before supply changes take effect.

Compounded peptides like BPC-157, CJC-1295, and ipamorelin exist in a separate regulatory space: they are not FDA-approved as drugs, and their compounding is permitted only under strict 503A rules (patient-specific prescriptions from licensed practitioners). Purchasing these peptides from online "research chemical" vendors without a prescription is illegal and carries significant quality-control risks, including contamination and mislabeling.

Deeper Reads: HealthRX Peptide Articles

Each of the following links goes to a full evidence review on a specific peptide:

• Semaglutide for Weight Loss: Full Clinical Guide
• Tirzepatide vs. Semaglutide: Head-to-Head Comparison
• CJC-1295 and Ipamorelin: Growth Hormone Protocol Guide
• BPC-157: What the Evidence Actually Says
• PT-141 (Bremelanotide) for Sexual Health
• Tesamorelin: FDA-Approved GHRH Analogue